

CONVENIENT RUTHENIUM-COMPLEX CATALYSED SYNTHESIS OF ENTEROLACTONE  
FROM THE CORRESPONDING DIBENZYLIDENE SUCCINIC ACID MOIETY

Massimo Bambagiotti-Alberti<sup>\*</sup>, Silvia A. Coran, Franco P. Vinciari,  
and Pierandrea Lo Nostro<sup>1</sup>

Dipartimento di Scienze Farmaceutiche dell'Università  
Via Gino Capponi 9, 50121 Firenze, Italy

**Abstract** - A convenient synthesis of enterolactone is outlined consisting mainly of a ruthenium carbonyl-hydride complex catalysed hydrogenation of bis(3-methoxybenzylidene)succinic acid.


The recent discovery of enterolactone (2,3-bis(3-hydroxybenzyl)-4-butanolide) in human and various animal excretions<sup>2-6</sup> has prompted a renewed interest in the lignans, a well-known class of plant natural products<sup>7-10</sup> to which the above mentioned compound of animal origin can also be ascribed.

Many plant lignans exhibit a variety of biological activities<sup>11-13</sup> the most important being proven anticancer capabilities<sup>14-23</sup>. Consequently, a great wealth of research has been undertaken in the last five years on the role of enterolactone in human metabolism, which has also finally been regarded as a sort of endogenous protective agent connected to certain types of cancer<sup>24</sup>. Shortage of synthetic enterolactone for extensive biological tests has been, however, a common complaint in almost every paper concerned with this topic. To meet this requirement several syntheses based on multi-step procedures have been promptly proposed<sup>25-27</sup>.

In order to obtain enterolactone (1) we exploited the ability of the soluble ruthenium carbonyl-hydride complex  $H_4Ru_4(CO)_8(PBu_3)_4$  to catalyse the gamma-lactone ring formation<sup>28,29</sup> starting from the succinic acid moiety, obtained via the Stobbe condensation, in one step under usual high pressure catalytic hydrogenation conditions.

Bis(3-methoxybenzylidene)succinic acid (2) (mp 183-185°C from MeOH; ir (nujol): 3200-2200, 1683  $cm^{-1}$ ; <sup>1</sup>H nmr (60 MHz, DMSO-d<sub>6</sub>): 7.85(2H, =CH), 7.5-6.8 (8H, Ar-H), 3.70 (6H, OCH<sub>3</sub>); ms: M<sup>+</sup> 354(4), 336(56), 291(19), 264(12), 229(100), 108(65) m/z) was obtained by an improved Stobbe condensation in 50.5% yield (13.1g) by refluxing (2 h) in anhydrous toluene 3-methoxybenzaldehyde (21g, 154mmol), dimethyl succinate (10.7g, 73mmol) and NaH (3.6g, 150mmol, dry powder). A catalytic amount of prepared Ru-catalyst (50mg)<sup>30</sup> and 2 (12.5g) were dissolved in toluene and the

solution placed in a high pressure autoclave. After 24 h at 170°C under hydrogen at 270-300 bars, a complete conversion to 2,3-bis(3-methoxybenzyl)-4-butanolide (**3**) (Found:  $M^+$  326.1518.  $C_{20}H_{22}O_4$  requires  $M^+$  326.1518) was achieved by the simultaneous occurrence of double-bond saturation and butanolide formation. The reaction course was advantageously followed by mass spectrometry in the "direct electron impact" mode<sup>31</sup> allowing direct periodic monitoring of the crude reaction mixture ( $M^+$  of **2** =  $m/z$  354,  $M^+$  of **3** =  $m/z$  326). Gas chromatography (fused silica capillary column and PTV injector) and mass spectrometry (EI) revealed **3** as a 4:1 mixture of the trans- and cis-isomers the more abundant of which being the trans-form.



The toluene solution was dried and evaporated, the residue (11.5g) was treated with cold 1% methanolic potassium hydroxide solution (24 h) to obtain a complete conversion to the trans-form<sup>32</sup>. The exhausted ruthenium-complex catalyst was finally removed by solvent extraction (hexane, MeOH-aq 90%) giving trans-**1** dimethylether in 49% overall yield (colorless gum from dry column chromatography (silica gel and  $CH_2Cl_2$ ); ir (neat): 2838, 1771  $cm^{-1}$ ;  $^1H$  nmr (200 MHz,  $CDCl_3$ ): 2.40-2.70 (m, H-2, H-3, H-5a, H-5b), 2.50 (dd, H-6b), 3.06 (dd, H-6a), 3.75 (6H,  $-OCH_3$ ), 3.86 (dd, H-4b), 4.10 (dd, H-4a), 6.5-7.3 (8H, arom.); ms:  $M^+$  326(38), 205(15), 191(3), 159(13), 147(27), 135(9), 122(100), 121(60), 117(7), 107(8), 91(31), 77(12)). Demethylation of this dimethylether with boron tribromide<sup>25</sup> gave

trans-1 (8.2g) with spectroscopic data in agreement with those reported in the literature<sup>25,33</sup>.

Further work is currently in progress for the full exploitation of this process to synthesize other lignans having a butanolide ring in their molecule.

#### ACKNOWLEDGMENTS

This research was supported by the Italian Consiglio Nazionale delle Ricerche within the program "Progetti Finalizzati Chimica Fine e Secondaria, Ca2".

Thanks are due to Profs. M.Bianchi and U.Matteoli, of this University, for helpful discussion and for making hydrogenation apparatus available.

#### REFERENCES

1. Taken partly from his Tesi di Laurea in Chimica
2. S.R.Stitch, J.K.Toumba, M.B.Groen, C.W.Funke, J.Leemhuis, J.Vink and G.F.Woods, *Nature*, 1980, **287**, 738.
3. K.D.R.Setchell, A.M.Lawson, F.L.Mitchell, H.Adlercreutz, D.N.Kirk and M.Axelson, *Nature*, 1980, **287**, 740.
4. H.Adlercreutz, T.Fotsis, R.Heikkinen, J.T. Dwyer, B.R.Goldin, S.L. Gorbach, A.M.Lawson and K.D.R.Setchell, *Med.Biol.*, 1981, **59**, 259.
5. S.P.Borriello, K.D.R. Setchell, M.Axelson and A.M. Lawson, *J. Applied Bacteriology*, 1985, **58**, 37.
6. K.D.R.Setchell, A.M.Lawson, E.Conwaj, N.F.Taylor, D.M.Kirk, G.F.Cooley, R.D.Farrant, S.Wynn and M.Axelson, *Biochem.J.*, 1981, 447.
7. C.B.S.Rao, "The Chemistry of Lignans", Andhra University Press, Waltair, 1978.
8. W.M.Hearon and W.S. MacGregor, *Chem. Rev.*, 1955, **55**, 957.
9. R.S.Ward, *Chem. Soc. Rev.*, 1982, **11**, 75.
10. A.Chatterjee, A.Banerji and J.Banerji, *Proc.Indian Acad.Sci.(Chem.Sci.)*, 1984, **93**, 1031.
11. M.Axelson, J.Sjovall, B.E.Gustafsson and K.D.R.Setchell, *Nature*, 1982, **298**, 659.
12. T.Markannen, M.Markinen, E.Maunuksela and P.Himanen, *Drug Under Exp. Clin. Res.*, 1981, **7**, 711.
13. W.D.MacRae and G.H.Towers, *Phytochemistry*, 1984, **23**, 1207.
14. K.Tomioka and K.Koga, *Tetrahedron Lett.*, 1979, 3315.
15. J.Leiter, V.Dowing, J.L.Hartwell and M.J.Shear, *J.Nat.Cancer Inst.*, 1950, **10**, 1273.
16. P.B.McDoniel and J.R.Cole, *J.Pharm.Sci.*, 1972, **61**, 1992.
17. H.Stahelin, *Eur. J. Cancer*, 1973, **9**, 215.
18. S.J.Torrance, J.J.Hoffman and J.R.Cole, *J.Pharm.Sci.*, 1979, **68**, 664.
19. K.N.Campbell, J.A.Cella and B.K.Campbell, *J.Am.Chem.Soc.*, 1953, **75**, 4681.
20. J.R.Cole, E.Bianchi and E.R.Trumbull, *J.Pharm.Sci.*, 1969, **58**, 175.
21. E.M.Greenspan, J.Leiter and M.J.Shear, *J.Nat. Cancer Inst.*, 1950, **10**, 1295.

22. D.A. Cairnes, O. Ekundayo and D.G.I. Kingston, *J. Nat. Prod.*, 1980, 43, 495.
23. L. Bézanger-Beauquesne, *Plantes méd. Phytothér.*, 1982, 16, 206.
24. H. Adlercreutz, R. Heikkinen, M. Woods, T. Fotsis, J.T. Dwyer, B. Goldin and S.L. Gorbach, *Lancet*, 1982, 1295.
25. A. Pelter, R.S. Ward, P. Satyanarayana and P. Collins, *J. Chem. Soc. Perkin Trans. I*, 1983, 643.
26. G. Cooley, F.D. Farrant, D.N. Kirk and S. Wynn, *Tetrahedron Lett.*, 1981, 22, 349.
27. M.B. Groen and J. Leemhuis, *Tetrahedron Lett.*, 1980, 21, 5043.
28. M. Bianchi, G. Menchi, F. Francalanci, F. Piacenti, U. Matteoli, P. Frediani and C. Botteghi, *J. Organomet. Chem.*, 1980, 188, 109.
29. M. Bambagiotti-Alberti, S.A. Coran, V. Giannellini and F.F. Vincieri, *Atti XV Congresso Nazionale S.C.I.*, Grado, 1984, p.146.
30. F. Piacenti, M. Bianchi, P. Frediani and E. Benedetti, *Inorg. Chem.*, 1971, 10, 2759.
31. P. Traldi, U. Vettori and F. Dragoni, *Org. Mass Spectrom.*, 1982, 17, 587.
32. R.D. Haworth and J.R. Atkinson, *J. Chem. Soc.*, 1938, 797.
33. J. Harmatha, M. Budesinsky and A. Trka, *Collect. Czech. Chem. Commun.*, 1982, 47, 644.

Received, 3rd March, 1987